Glenn Flux

Royal Marsden Hospital
Head of radioisotope physics

Dr Glenn Flux is Head of Radioisotope Physics at the Royal Marsden Hospital and Institute of Cancer Research in Sutton, UK. His main research focus is on translational quantitative SPECT and PET imaging and its application to internal dosimetry for molecular radiotherapy. He has been involved in the development of imaging and dosimetry for clinical procedures including I-131 mIBG treatment of neuroblastoma and the treatment and palliation of bone metastases from prostate cancer with Re-186 HEDP and Ra-223. He has published over 100 peer reviewed articles and received research funding from national and international bodies. He is a founder member of the EANM Dosimetry Committee and is currently chair of the British Nuclear Medicine Society Molecular Radiotherapy committee.

dont miss

The emergence and resurgence of radiotherapeutics for cancer treatment

Cancer treatment with radiopharmaceuticals is growing rapidly with many new radiotherapeutics either in development or early phase trials. Molecular radiotherapy and theragnostics promise to offer significant advances in cancer care and the market is expected to grow by 30% per annum for the foreseeable future. This presentation will review the potential impact of this expansion for industry, academia, and patient benefit.

EVEN MORE SEMINARS

  • Profess Liz Ward: Speaking at the Oncology Convention

    Profess Liz Ward
    Centre for Functioning and Health Research, Metro South Hospital and Health Service, and The Univers

    Laryngectomy rehabilitation: Opportunities for improving speech pathology supports via telehealth

  • Laura Allington: Speaking at the Oncology Convention

    Laura Allington
    University College London Hospitals NHS Foundation Trust

    Operational challenges of planning a new NHS high energy proton service.

  • Merina Ahmed: Speaking at the Oncology Convention

    Merina Ahmed
    Royal Marsden NHS foundation Trust

    Stereotactic Radiotherapy for lung tumours and oligometastatic disease

  • Nirmesh Patel: Speaking at the Oncology Convention

    Nirmesh Patel
    Cambridge Cancer Genomics

    Monitoring cancer evolution through smart genomics and liquid biopsies

  • Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd: Speaking at the Oncology Convention

    Imran Liaquat MBChB BSc MedSci MRCS FRCS MEd
    NHS Lothian, Scotland

    Optimising Surgical Resection in Low Grade Glioma Patients